Loading data for GOSS — first visit, this takes a few seconds.
Gossamer Bio Inc. (GOSS)
NasdaqGS: GOSS
· Real-Time Price · USD
0.16
+0.02 (14.29%)
At close: Aug 19, 2026, 8:00 PM
0.16
+1.72%
After-hours: 7:30 PM
Gossamer Bio Inc. (GOSS) Stock Price, Analysis & Data
14.29% (1D)
No data available
| Bid | 0.14 |
| Market Cap | 76.55M |
| Revenue (ttm) | 53.29M |
| Net Income (ttm) | -125.22M |
| Beta | n/a |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.87 |
| P/B (ttm) | -0.23 |
| P/S (ttm) | 1.44 |
| Earnings Date | n/a |
| Ask | 0.16 |
| Volume | 6,450,948 |
| Avg. Volume (20D) | 25,726,006 |
| Open | 0.15 |
| Previous Close | 0.14 |
| Day's Range | 0.14 - 0.16 |
| 52-Week Range | 0.11 - 3.87 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About GOSS
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It ha...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 8, 2019
Employees 161
Stock Exchange NasdaqGS
Ticker Symbol GOSS
Website https://www.gossamerbio.com
Financial Performance
In 2025, Gossamer Bio's revenue was 48.47M, a decrease of -57.74% compared to the previous year's 114.7M. Earnings were -170.37M, an increase of 201.39%.
Financial Statements